Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted ...

They revealed during the reunion on March 11 that they split after four months During the sit-down, Morrison claimed Faeth wasn't ready for marriage, while he said trust issues "took a toll" on their ...

New R&D program for tyrosinemia type 1 (TT1) demonstrates how metabolism-targeted discovery extends from cancer into rare pediatric disease Faeth R&D is supported by MetabOS, a computational model ...

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has changed its corporate name to Faeth Therapeutics, Inc. (the "Company"). The Company’s common stock is expected to begin trading ...

Faeth Therapeutics is a clinical-stage biotechnology company integrating targeted therapies with precision nutrition interventions to exploit metabolic vulnerabilities in cancer. Founded by renowned ...

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Faeth), a clinical biotechnology company focused on rethinking the science of cancer using metabolism, announced the appointment of Dr. Stephen Hahn ...

A hot bowl of pad thai simmers in front of you. The taste and texture is exactly what you might expect from a quick takeout dinner, but it's not just a meal -- it’s medicine. This hypothetical bowl of ...

New $25 million raise advances multi-node PI3K program; randomized phase 2 trial with Gynecologic Oncology Group Foundation now enrolling Faeth Therapeutics, a clinical-stage biotechnology company ...

The latest update is out from Faeth Therapeutics ( (FTH) ).

Over the years dozens of health nuts and fitness gurus have claimed, untruthfully, that it is possible to cure cancer with a change in diet. Now a new startup has a similar proposition — but it's ...

- Founding team includes the world’s leading cancer researchers and clinicians including Drs. Lew Cantley, Sid Mukherjee, Karen Vousden and others SAN FRANCISCO--(BUSINESS WIRE)--Faeth Therapeutics, a ...

New R&D program for tyrosinemia type 1 (TT1) demonstrates how metabolism-targeted discovery extends from cancer into rare pediatric disease AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, a ...